Beneficial effects of edaravone, a novel antioxidant, in rats with dilated cardiomyopathy.

Authors:
Address: Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata City, 956-8603, Japan.
Journal:

Publication:

abstract

edaravone, a novel antioxidant acts by trapping hydroxyl radicals, quenching active oxygen and so on. Its cardioprotective activity against experimental autoimmune myocarditis (EAM) was reported. Nevertheless, it remains to be determined whether edaravone protects against cardiac remodeling in dilated cardiomyopathy (DCM). The present study was undertaken to assess whether edaravone attenuates myocardial fibrosis and examine the effect of edaravone on cardiac function in rats with DCM after EAM. Rat model of EAM was prepared by injection with porcine cardiac myosin. 28 days after immunization, we administered edaravone intraperitoneally at 3 and 10 mg/kg/day to rats for 28 days. The results were compared with vehicle treated rats with DCM. Cardiac function, by hemodynamic and echocardiographic study and histopathology were performed. Left ventricular (LV) expression of NADPH oxidase subunits (p47(phox) , p67(phox) , gp91(phox) and Nox4), fibrosis markers (TGF-β1 and OPN), endoplasmic reticulum (ER) stress markers (GRP78 and GADD 153) and apoptosis markers (cytochrome C and caspase-3) were measured by Western blotting. Edaravone treated DCM rats showed better cardiac function compared with those of the vehicle treated rats. In addition, LV expressions of NADPH oxidase subunits levels were significantly down-regulated in edaravone-treated rats. Furthermore, the number of collagen-III positive cells in the myocardium of edaravone treated rats was lower compared with those of the vehicle treated rats. Our results suggest that edaravone ameliorated the progression of DCM by modulating oxidative and ER stress mediated myocardial apoptosis and fibrosis. © 2012 The Authors Journal of Cellular and Molecular Medicine © 2012 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.

Related Articles
The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis.
Free Radic Res. 2010
The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis.
Shimazaki H, Watanabe K, Veeraveedu PT, Harima M, Thandavarayan RA, Arozal W, Tachikawa H, Kodama M, Aizawa Y. Free Radic Res. 2010 Sep; 44(9):1082-90.
Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis.
Life Sci. 2012
Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis.
Sukumaran V, Veeraveedu PT, Gurusamy N, Lakshmanan AP, Yamaguchi K, Ma M, Suzuki K, Kodama M, Watanabe K. Life Sci. 2012 Feb 13; 90(7-8):289-300. Epub 2011 Dec 19.
Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.
Exp Biol Med (Maywood). 2010
Beneficial effects of olmesartan, an angiotensin II receptor type 1 antagonist, in rats with dilated cardiomyopathy.
Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y. Exp Biol Med (Maywood). 2010 Nov; 235(11):1338-46. Epub 2010 Sep 27.
Review Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis.
Inflamm Allergy Drug Targets. ...
Review Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis.
Watanabe K, Sukumaran V, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, Arozal W, Sari FR, Lakshmanan AP, Arumugam S, et al. Inflamm Allergy Drug Targets. 2011 Jun; 10(3):218-25.
Review Inflammatory dilated cardiomyopathy (DCMI).
Herz. 2005
Review Inflammatory dilated cardiomyopathy (DCMI).
Maisch B, Richter A, Sandmöller A, Portig I, Pankuweit S, BMBF-Heart Failure Network. Herz. 2005 Sep; 30(6):535-44.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.